GLPG Galapagos

    Mechelen, Belgium; 28 November 2006  - Galapagos NV (Euronext &  LSE:
GLPG) announced  today that  its service  division BioFocus  DPI  has
extended its  International  Standards Organization's  ISO  9001:2000
certification to  cover its  Target Discovery  operations in  Leiden.
 BioFocus DPI first received certification for its Cambridge site  in
2003.  The extension to Leiden follows on an external audit performed
by Lloyds Register of Quality Assurance (LRQA), a UKAS and Dutch  RvA
accredited quality certification body.

The scope of  BioFocus DPI's  certification covers  its provision  of
biological   and   chemical   research   for   the    pharmaceutical,
biotechnology  and  agrochemical   industries.    ISO   9001  is   an
internationally accepted  standard  that represents  good  management
practices and aims to ensure that organizations consistently  deliver
products or services that meet their clients' quality requirements.

"This certification  reflects our  commitment to  excellence in  drug
discovery and the professionalism and hard work of all our staff.  We
intend to build on our success in Leiden, as we strive to exceed  our
customers' expectations," said Chris Newton, Senior Vice President of
BioFocus DPI.

About Galapagos

Galapagos is a publicly traded, genomics-based drug discovery company
(Euronext Brussels,  GLPG;  Euronext Amsterdam,  GLPGA,  London  AiM:
GLPG) that has  drug discovery programs  based on proprietary,  novel
targets in bone and joint diseases - osteoarthritis, osteoporosis and
rheumatoid  arthritis.      Galapagos   offers  a   full   suite   of
target-to-drug discovery products and services to pharmaceutical  and
biotech companies  through its  division BioFocus  DPI,  encompassing
target discovery and drug discovery  services through to delivery  of
pre-clinical  candidates.    In   addition,  BioFocus  DPI   provides
adenoviral reagents for rapid identification and validation of  novel
drug targets and  compound libraries for  drug screening.   Galapagos
currently employs  more  than 330  people,  including 144  PhDs,  and
operates facilities in seven  countries, with global headquarters  in
Mechelen, Belgium.  More information about Galapagos and BioFocus DPI
can be found at www.glpg.com.

CONTACT

BioFocus DPI
Chris Newton, Senior Vice President
Tel: + 44 1799 533535
ir@glpg.com

This  release  may  contain  forward-looking  statements,  including,
without  limitation,  statements  containing  the  words  "believes,"
"anticipates," "expects," "intends,"  "plans," "seeks,"  "estimates,"
"may," "will,"  "could," "stands  to," and  "continues," as  well  as
similar expressions.   Such  forward-looking statements  may  involve
known and unknown risks, uncertainties and other factors which  might
cause  the  actual  results,  financial  condition,  performance   or
achievements of  Galapagos, or  industry  results, to  be  materially
different from any historic or future results, financial  conditions,
performance  or   achievements   expressed   or   implied   by   such
forward-looking statements.  Given these uncertainties, the reader is
advised not  to  place any  undue  reliance on  such  forward-looking
statements.  These  forward-looking statements speak  only as of  the
date of publication of this document.  Galapagos expressly  disclaims
any obligation to update any such forward-looking statements in  this
document to  reflect  any  change in  its  expectations  with  regard
thereto or any change in events, conditions or circumstances on which
any such statement is based, unless required by law or regulation.

- ---END OF MESSAGE---






Copyright � Hugin ASA 2006. All rights reserved.

Galapagos (LSE:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024

Galapagos (LSE:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024